When does genomics become eugenics?
By Eben Kirksey,
Financial Review
| 12. 11. 2020
As the tools to identify human traits and manipulate them become more refined, ideas about normalcy and deviancy, fitness and disability, are subtly changing.
Simply Google “BGI NIFTY” and you will find a slick website from China’s premier genomics company offering new options in the quest for quality children. This screening technology has already been used in more than 62 countries in Asia, Europe, the Americas, and the Middle East.
The NIFTY webpage has a “decision calculator” to see if you should mitigate the risks of your pregnancy. An embedded YouTube video offers a perspective from a young white couple. They talk in British accents about the importance of accuracy, saying that they are willing to pay for the best prenatal care on the market. An older single woman says that this will be her first and perhaps only baby, and she wants to make sure that nothing is wrong.
Previously in China, under the controversial one-child policy, couples were encouraged to make the most of their only shot. Amniocentesis – the insertion of a needle through the abdominal skin into the uterus to extract amniotic fluid which is then tested – was promoted by government experts as part of the practice...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
